Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors. Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical molecular signal analysis. With Cardean transistors, the company and its Innovation Partners can